Why is there a 'renaissance' in psychedelic research?

After a promising period of research in the 1950s and 60s, studies were halted due to the counterculture's embrace of psychedelics and subsequent moral panic. The current Renaissance is driven by desperation with failing mental healthcare systems and renewed scientific interest in psychedelics' therapeutic potential.

What conditions are showing promise for psychedelic treatment?

Research indicates potential benefits for addiction (alcoholism, smoking), depression (major and treatment-resistant), anxiety in terminally ill cancer patients, eating disorders, OCD, and potentially other behavioral changes by helping individuals break out of destructive thought loops.

How do psychedelics achieve lasting effects if their half-life is short?

The lasting effects are attributed to the profound psychological experience, particularly ego dissolution and mystical experiences, rather than purely pharmacological action. These experiences can be deeply transformative, akin to a 'reverse trauma,' offering new perspectives and insights that persist long after the drug wears off.

What is the role of the 'default mode network' in psychedelic experiences?

The default mode network, associated with ego function and self-reflection, is suppressed during psychedelic use. This quieting allows other brain regions to communicate more freely, potentially leading to ego dissolution and increased interconnectedness. Similar suppression is observed in experienced meditators.

Which psychedelic compounds are currently the focus of research and why pseudopsilocybin?

While LSD, DMT, and ibogaine are known, psilocybin is frequently researched due to its shorter half-life (fitting within a therapist's workday), less political controversy compared to LSD, and its manageable duration (4-6 hours).

What are the main challenges preventing wider access to psychedelic therapies?

Key challenges include scarcity of funding (most research is privately funded), the 'Schedule 1' drug classification, the lack of government funding for mental health research, and the difficulty in integrating these unique, experience-based treatments into existing healthcare and therapy business models.

What are the primary risks associated with psychedelic use?

The main risks are psychological, including the potential for traumatizing experiences or triggering latent mental health issues like schizophrenia if used improperly. Physiological risks are generally considered low. These risks are significantly mitigated by experienced guidance and a safe setting.

How are psychedelics like MDMA and psilocybin progressing through the FDA approval process?

Both MDMA (for PTSD) and psilocybin have received 'breakthrough therapy' status from the FDA, which actively helps researchers accelerate trials. MDMA is already in Phase 3 trials, and approval for both is anticipated within the next five years.

Can psychedelics be considered a 'panacea' for all mental health issues?

No, psychedelics are not a panacea. While promising for conditions often considered intractable, they may not be effective for all disorders (e.g., highly chaotic states like schizophrenia). Current research suggests they may address a common underlying issue of 'stuckness' or rigidity in the brain.

What are the most exciting developments in psychedelic research since Michael Pollan's book was published?

Exciting developments include the increasing mainstreaming of the topic, open discussions about experiences, and major psychiatric departments at universities like Yale and Columbia initiating research. There's also growing interest in applying psychedelics to a wider range of conditions beyond depression.

How can individuals learn more or potentially contribute to psychedelic research?

Resources include documentaries like 'Trip of Compassion' and 'Fantastic Fungi,' books such as 'How to Change Your Mind,' and scientific papers by researchers like Robin Carhartt Harris. Financial contributions to labs at Johns Hopkins, NYU, or UCSF, or organizations like MAPS, are highly leveraged investments.

Key Moments

The Frontiers of Psychedelics — Michael Pollan

Tim Ferriss

Howto & Style3 min read90 min video

Mar 21, 2019|857,792 views|8,995|722

tim ferriss 4 hour workweek 4 hour body timothy ferriss entrepreneur author writer best-seller public speaker angel investor ferriss tim ferriss blog

Save to Pod

Key Moments

TL;DR

Psychedelics offer new hope for mental health, consciousness studies, and addiction treatment.

Key Insights

Psychedelic research, halted in the 60s, is experiencing a significant renaissance due to promising results in treating addiction, depression, and end-of-life anxiety.

The core therapeutic mechanism likely involves ego dissolution, allowing individuals to break free from destructive thought patterns and gain new perspectives.

While the FDA is moving towards approving MDMA and psilocybin, funding and integration into existing healthcare models remain challenges.

Psychedelics are not a panacea but may be effective for "stuckness" and rigid thought patterns, potentially revealing deeper insights into the nature of mental illness.

The scientific understanding of how psychedelics work is still developing, with theories focusing on the default mode network and altered brain wave patterns.

Risks, particularly psychological ones and potential for abuse in unregulated settings, are real but can be mitigated by experienced guidance and safe environments.

DEFINING PSYCHEDELICS AND THEIR HISTORY

The term 'psychedelic,' coined in the 1950s, means 'mind-manifesting.' Initially thought to mimic psychosis, researchers discovered they induced often ecstatic experiences. After a promising period of research in the 1950s and early 60s for conditions like addiction and depression, research halted due to counterculture adoption and subsequent moral panic. This period saw the drugs demonized by media and government, leading to a research dark age until the present renaissance.

THE RESURGENCE OF PSYCHEDELIC RESEARCH

Current research, notably at institutions like Johns Hopkins and NYU, is exploring psychedelics for various conditions. Initial studies on cancer patients facing end-of-life anxiety showed remarkable fear reduction. Research is now advancing for depression (including treatment-resistant forms), addiction (alcoholism, smoking), and potentially eating disorders and OCD, leveraging the drugs' ability to disrupt repetitive, destructive thought loops.

MECHANISMS OF ACTION: EGO DISSOLUTION AND PERSPECTIVE SHIFTS

The enduring effects of psychedelics are attributed not just to their short-acting pharmacology but the profound experience they induce. A key element is ego dissolution, temporarily quieting the default mode network (DMN), which is associated with self-referential thought and ego maintenance. This allows for a dissolution of the subject-object duality, fostering feelings of connection and love, and offering a new perspective on personal narratives and destructive behaviors.

THE NOETIC QUALITY AND PERSONAL TRANSFORMATION

Experiences with psychedelics, particularly at high doses, can possess a 'noetic quality,' where insights feel like revealed truths rather than mere opinions. This profound sense of understanding, often occurring after ego dissolution, can lead to lasting behavioral changes. For example, an individual struggling with addiction might gain a deep, unshaken conviction about the consequences of their actions, leading to sustained recovery.

VARIETIES OF PSYCHEDELICS AND THEIR RESEARCH PROSPECTS

While LSD and psilocybin are common, different psychedelics like DMT and ibogaine are also being studied. Psilocybin currently shows strong practical prospects due to its manageable half-life and less controversial public perception, making it easier to integrate into therapeutic settings. MDMA is further along in FDA trials, particularly for PTSD, demonstrating significant progress in medical acceptance.

NAVIGATING THE CHALLENGES: FUNDING, REGULATION, AND THERAPEUTIC MODELS

Despite promising research, challenges include securing adequate funding, as most research is privately financed. Integrating psychedelics into healthcare is complex; the pharmaceutical and therapy industries, reliant on long-term drug regimens or weekly sessions, may not readily adopt treatments involving single or few profound experiences. The unapproved 'underground' offers access but carries risks of unqualified practitioners and potential for abuse.

UNDERSTANDING THE RISKS AND MITIGATING FACTORS

While physiologically low in toxicity, psychedelics carry psychological risks, including the potential to trigger latent psychosis or lead to traumatizing experiences if used in unsafe settings. These risks are significantly reduced in guided, therapeutic environments. An experienced guide can prepare individuals, offer support during the experience, and aid in integrating the insights gained, emphasizing surrender and acceptance of challenging experiences.

THE FUTURE: MAINSTREAMING, NEW RESEARCH AVENUES, AND INVESTMENT

The increasing acceptance and discussion of psychedelics, even in mainstream medical institutions, signifies a positive shift. Future research could explore their use with various populations, including those with life-altering diagnoses beyond depression and addiction. Investment in labs and research centers is crucial. Psychedelics are also vital tools for understanding consciousness itself, potentially offering insights into the nature of mental illness and the self.

Mentioned in This Episode

●Organizations

●Books

●Drugs & Medications

●Concepts

●People Referenced

Common Questions

The term 'psychedelic' was coined in 1957 by psychiatrist Humphry Osmond from the Greek words 'psyche' (mind) and 'delos' (manifesting), meaning 'mind manifesting.' It suggests these substances bring the mind into an observable state.

Topics

Health & Longevity Neuroscience & the Brain Mindset & Self-Improvement Psychedelic Therapy Ego Dissolution Neuroscience Research Consciousness Studies Mental Health Innovation Drug Policy Reform Mystical Experiences

Mentioned in this video

Supplements

DMT

Dimethyltryptamine, a potent psychedelic compound found in ayahuasca. In its pure chemical form, it's fast-acting and short-lived, with some potential for research.

Drugs & Medications

Ayahuasca

A brewed psychoactive beverage originating from South America, containing DMT. Research is being done in Brazil on its use for depression, though its complex plant-based nature makes standardization difficult for studies.

psilocybin

The psychoactive compound found in magic mushrooms, currently being researched for its therapeutic potential in treating depression, addiction, and anxiety, especially in cancer patients. It has a shorter half-life than LSD, making it practical for therapy sessions.

LSD

Lysergic acid diethylamide, a powerful and long-lasting psychedelic compound. Historically associated with controversy and counterculture, it is less commonly used in current research due to political reasons.

Ibogaine

A psychedelic compound mentioned as one of the 'usual suspects' in psychedelic research.

MDMA

3,4-Methylenedioxymethamphetamine, also known as ecstasy, is being used in Phase 3 trials for treating PTSD, particularly in veterans. It promotes a deep bond of trust with therapists.

Ketamine

An anesthetic that also has psychedelic effects at sufficient doses. It was recently approved and is considered one of the WHO's essential medicines. It's being used in legal clinics as a therapeutic option.

People

Aldous Huxley

Author of 'The Doors of Perception,' which recorded his mescaline trip. He collaborated with Humphry Osmond in conceptualizing psychedelic substances.

Timothy Leary

A figure associated with the 1960s 'counterculture' who was instrumental in popularizing psychedelic drug use.

Humphry Osmond

English psychiatrist who coined the term 'psychedelic' in 1957 in a dialogue with Aldous Huxley.

Alison Gopnik

A psychologist at UC Berkeley who studies child psychology. She posits that young children experience an 'altered state of consciousness' akin to psychedelics, characterized by 'lantern consciousness.'

Rick Doblin

Head of MAPS (Multidisciplinary Association for Psychedelic Studies). He has been a key figure driving the psychedelic renaissance, advocating for legal and therapeutic use since 1985.

Michael Pollan

Author of 'How to Change Your Mind,' discussing the new science and personal experiences with psychedelics. He is a professor of science journalism at Harvard and UC Berkeley.

William James

Psychologist who described the 'noetic quality' of mystical experiences, referring to the feeling of gaining revealed truth or actual knowledge.

Maria Sabina

A legendary Mazatec healer who first introduced psilocybin to a Westerner in 1956, referenced during Michael Pollan's personal psychedelic experience.

Stanislav Grof

A prominent psychedelic psychiatrist known for his work in the 1960s and 70s. He proposed that psychedelics could be to the study of the mind what the telescope is to astronomy.

Books

The Psychedelic Explorer's Guide

A book by James Fadiman offering advice for those seeking or choosing a psychedelic guide, including reprinted codes of conduct for guides.

The Doors of Perception

A book by Aldous Huxley detailing his experiences with mescaline, relevant to the early understanding of psychedelic substances.

Media

Trip of Compassion

A documentary showcasing MDMA-assisted psychotherapy sessions for PTSD, created by Israeli filmmakers and recently made available digitally.

Fantastic Fungi

A documentary covering the complexity of fungi and mycelium, as well as psychedelic research at institutions like Johns Hopkins and NYU. Michael Pollan makes a cameo appearance.

Concepts

Default Mode Network

A network of brain regions that becomes active when an individual is not focused on the outside world. It's implicated in self-referential thought, ego function, and 'time travel' (thinking about past/future). Psychedelic use and meditation can suppress its activity.

Organizations

NIH

The National Institutes of Health, which has a limited budget primarily dedicated to drug abuse research. Insufficient funding for mental health research is a bottleneck for psychedelic studies.

FDA

The Food and Drug Administration, which has granted 'breakthrough therapy' status to psilocybin and MDMA, actively assisting researchers in moving these drugs toward approval.

MAPS

Multidisciplinary Association for Psychedelic Studies, focused on MDMA research for PTSD and other psychedelic work. They publish resources for guides and need funding for their clinical trials.